Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mavorixafor
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : X4 Pharmaceuticals
Deal Size : $260.5 million
Deal Type : Licensing Agreement
X4 Pharmaceuticals, Norgine Sign License for Mavorixafor in Europe, Australia
Details : Under the licensing agreement, Norgine will hold exclusive rights to commercialize Xolremdi (mavorixafor) in Europe, Australia, etc. It is being indicated for the treatment of WHIM syndrome.
Product Name : Xolremdi
Product Type : Other Small Molecule
Upfront Cash : $29.1 million
January 13, 2025
Lead Product(s) : Mavorixafor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : X4 Pharmaceuticals
Deal Size : $260.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Norgine Submits DFMO Marketing Application to EMA for Neuroblastoma
Details : Iwilfin (eflornithine) is a USFDA approved ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma.
Product Name : Iwilfin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2025
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Norgine Submits MAA for Eflornithine in High-Risk Neuroblastoma via Project Orbis
Details : Iwilfin (eflornithine) is a USFDA approved ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma.
Product Name : Iwilfin
Product Type : Small molecule
Upfront Cash : Not Applicable
April 15, 2024
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dantrolene
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Norgine Receives Positive ChMP Opinion for NPJ5008 for Treating Malignant Hyperthermia
Details : NPJ5008 (dantrolene sodium hemiheptahydrate) is a RYR1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of malignant hyperthermia.
Product Name : NPJ5008
Product Type : Small molecule
Upfront Cash : Not Applicable
March 26, 2024
Lead Product(s) : Dantrolene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved
Recipient : Fennec Pharmaceuticals
Deal Size : $271.6 million
Deal Type : Licensing Agreement
Fennec and Norgine License PEDMARQSI for Europe, Australia, New Zealand
Details : Norgine will commercialize Pedmarqsi (sodium thiosulfate) in Europe, Australia, and New Zealand, the first approved therapy in the EU and UK to prevent cisplatin-induced ototoxicity.
Product Name : Pedmarqsi
Product Type : Small molecule
Upfront Cash : $43.4 million
March 18, 2024
Lead Product(s) : Sodium Thiosulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved
Recipient : Fennec Pharmaceuticals
Deal Size : $271.6 million
Deal Type : Licensing Agreement
Lead Product(s) : Sodium Chloride,Sodium Bicarbonate,Potassium Chloride
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Goldman Sachs Asset Management
Deal Size : Undisclosed
Deal Type : Financing
Norgine Announces Closing of Investment from Goldman Sachs Asset Management
Details : The macrogol in Movicol (sodium chloride) binds with water and retains it in the bowel. This allows the water to rehydrate and bulk the stool to trigger renewed colonic activity.
Product Name : Movicol
Product Type : Small molecule
Upfront Cash : Undisclosed
December 15, 2022
Lead Product(s) : Sodium Chloride,Sodium Bicarbonate,Potassium Chloride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Goldman Sachs Asset Management
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Study Phase : Phase II
Recipient : Covis Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ciraparantag is a novel small, water-soluble molecule being investigated for reversal of anticoagulation induced by direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH).
Product Name : PER977
Product Type : Small molecule
Upfront Cash : Not Applicable
October 04, 2021
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Recipient : Covis Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : US WorldMeds
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Norgine Enter Agreement to Commercialise DFMO in Independent States
Details : DFMO is a repurposed molecule investigated for use as an extended maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality thera...
Product Name : DFMO
Product Type : Small molecule
Upfront Cash : Undisclosed
July 23, 2021
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : US WorldMeds
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Study Phase : Phase II
Recipient : AMAG Pharmaceuticals
Deal Size : $290.0 million
Deal Type : Licensing Agreement
Details : Ciraparantag is in development for use in patients treated with direct oral anticoagulants and low molecular weight heparin when reversal of the anticoagulant effect of these products is needed for emergency surgery or due to life-threatening or uncontro...
Product Name : PER977
Product Type : Small molecule
Upfront Cash : $30.0 million
July 23, 2020
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Recipient : AMAG Pharmaceuticals
Deal Size : $290.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Potassium Chloride,Sodium Chloride,Ascorbic Acid
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Faes Farma
Deal Size : Undisclosed
Deal Type : Agreement
Norgine B.V. Inks Exclusive Licence and Distribution deal for PLENVU
Details : Norgine signed exclusive licence and distribution agreements with Faes Farma S.A., Pharmacare Limited T/A Aspen Pharmacare and Swixx Biopharma to provide worldwide exposure to PLENVU.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
February 12, 2020
Lead Product(s) : Potassium Chloride,Sodium Chloride,Ascorbic Acid
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Faes Farma
Deal Size : Undisclosed
Deal Type : Agreement